SLC16A1 and glioma: Further studies are needed to assess the utility of MCT inhibition as a treatment strategy for mutant IDH1 gliomas, but considering that the effectiveness of MCT inhibitors has been linked to MCT expression [78], inhibition of MCT expression and/or function likely would not provide a therapeutic opportunity for mutant IDH1 gliomas and this point should be considered in the planning of treatment for mutant IDH1 glioma patients.